Insights on Oral Drug Delivery of Lipid Nanocarriers: a Win-Win Solution for Augmenting Bioavailability of Antiretroviral Drugs
- 110 Downloads
The therapeutic functionality of innumerable antiretroviral drugs is supposedly obscured owing to their low metabolic stability in the gastrointestinal tract and poor solubilization property leading to poor oral bioavailability. Dictated by such needs, lipid-based formulations could be tailored using nanotechnology which would be instrumental in ameliorating the attributes of such drugs. The stupendous advantages which lipid nanocarriers offer including improved drug stability and peroral bioavailability coupled with sustained drug release profile and feasibility to incorporate wide array of drugs makes it a potential candidate for pharmaceutical formulations. Furthermore, they also impart targeted drug delivery thereby widening their arena for use. Therefore, the review will encompass the details pertaining to numerous lipid nanocarriers such as nanoemulsion, solid lipid nanoparticle, nanostructured lipid carriers, and so on. These nanocarriers bear the prospective of improving the mucosal adhesion property of the drugs which ultimately upgrades its pharmacokinetic profile. The biodegradable and physiological nature of the lipid excipients used in the formulation is the key parameter and advocates for their safe use. Nevertheless, these lipid-based nanocarriers are amenable to alterations which could be rightly achieved by changing the excipients used or by modifying the process parameters. Thus, the review will systematically envisage the impending benefits and future perspectives of different lipid nanocarriers used in oral delivery of antiretroviral drugs.
KEY WORDSlipids HIV nanoformulation oral drug delivery systems
Human immunodeficiency virus
Solid lipid nanoparticle
Nanostructured lipid carrier
Self nano emulsifying drug delivery systems
Highly active antiretroviral treatment
Blood cerebrospinal fluid barrier
The authors acknowledge Jamia Hamdard, New Delhi, India, for providing Jamia Hamdard Silver Jubilee Research Fellowship to the first author.
Compliance with Ethical Standards
Conflicts of Interest
The authors declare that they have no conflicts of interest.
- 17.Cao S, Woodrow KA. Nanotechnology approaches to eradicating HIV reservoirs. Eur J Pharm Biopharm. 2018. https://doi.org/10.1016/j.ejpb.2018.06.002.
- 25.Madureira AN, Campos DA, Oliveira A, Sarmento O, Pintado MM, Gomes A. Insights into the protective role of solid lipid nanoparticles on rosmarinic acid bioactivity during exposure to simulated gastrointestinal conditions. Colloids Surf B: Biointerfaces. 2016;139:277–84. https://doi.org/10.1016/j.colsurfb.2015.11.039.CrossRefPubMedGoogle Scholar
- 34.Kumar S, Narayan R, Ahammed V, Nayak Y, Naha A. Nayak UY, Development of ritonavir solid lipid nanoparticles by Box Behnken design for intestinal lymphatic targeting. J Drug Deliv Sci Technol. 2018. https://doi.org/10.1016/j.jddst.2017.12.014.
- 35.Savage AC, Tatham LM, Siccardi M, Scott T, Vourvahis M, Clark A, et al. Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. Eur J Pharm Biopharm. 2018. https://doi.org/10.1016/j.ejpb.2018.05.015.
- 38.Vivek M, Jain R, Patel K, Nivsarkar M, Joshi A. Solid lipid nanoparticles (SLN) of efavirenz as lymph targeting drug delivery system: elucidation of mechanism of uptake using chylomicron flow blocking approach. Int J Pharm. 2015;495:439–46. https://doi.org/10.1016/j.ijpharm.2015.09.014.CrossRefGoogle Scholar
- 54.Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: an advanced mode of drug delivery system. Biotech. 2015;5:123–7.Google Scholar
- 70.Makadia HA, Bhatt AY, Parmar RB, Paun JS, Tank HM. Self-nano emulsifying drug delivery system (SNEDDS): future aspects. Asian J Pharm Res. 2013;3:21–7.Google Scholar
- 72.Selvam RP, Kulkarni PK. Design and evaluation of self nanoemulsifying systems for poorly water soluble HIV drug. J Pharma Sci Tech. 2014;4(1):23–8.Google Scholar
- 73.Selvam RP, Kulkarni PK, Dixit M. Preparation and evaluation of self-nanoemulsifying formulation of efavirenz. Ind J Pharm Edu Res. 2013;47(1):47–54.Google Scholar
- 78.Obitte NC, Rohan LC, Adeyeye CM, Parniak MA, Esimone CO. The utility of self-emulsifying oil formulation to improve the poor solubility of the anti HIV drug CSIC. AIDS Res Ther. 2013;10(14):1–9.Google Scholar
- 81.Sahoo SK, Dash GS, Biswal S, Biswal PK, Senapati PC. Fabrication and evaluation of self-nanoemulsifying oil formulations (SNEOFs) of Efavirenz. J Dispers Sci Technol. 2018:1–12. https://doi.org/10.1080/01932691.2018.1472008.
- 85.Jindal AB, Bachhav SS, Devarajan PV. In situ hybrid nano drug delivery system (IHN-DDS) of antiretroviral drug for simultaneous targeting to multiple viral reservoirs: an in vivo proof of concept. Int J Pharm. 2017;521:196–203. https://doi.org/10.1016/j.ijpharm.2017.02.024.CrossRefPubMedGoogle Scholar